| P50 | author | Ulpu Saarialho-Kere | Q41600097 |
| | Tiina Skoog | Q55396188 |
| P2093 | author name string | Ulpu Saarialho-Kere | |
| | Pauli Puolakkainen | |
| | Tuula Kiviluoto | |
| | Susanna Virolainen | |
| | Ville Bister | |
| P2860 | cites work | Identification and characterization of human endometase (Matrix metalloproteinase-26) from endometrial tumor | Q22254053 |
| | Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4 | Q24322566 |
| | Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets | Q24672897 |
| | Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer | Q24801511 |
| | Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion | Q28240868 |
| | Association of matrilysin-2 (MMP-26) expression with tumor progression and activation of MMP-9 in esophageal squamous cell carcinoma | Q28279207 |
| | Matrix metalloproteinase-26 (matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer | Q28280551 |
| | Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets alpha1-antitrypsin serpin | Q28296132 |
| | New functions for the matrix metalloproteinases in cancer progression | Q29547738 |
| | Matrix metalloproteinase-21, the human orthologue for XMMP, is expressed during fetal development and in cancer | Q34165786 |
| | Matrix metalloproteinase-21 is expressed epithelially during development and in cancer and is up-regulated by transforming growth factor-beta1 in keratinocytes | Q34285779 |
| | Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer | Q34325639 |
| | Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. | Q34398447 |
| | Matrix metalloproteinases 21 and 26 are differentially expressed in esophageal squamous cell cancer | Q34518114 |
| | Molecular prognostic markers in pancreatic cancer: a systematic review | Q34560651 |
| | MMP-21 is expressed by macrophages and fibroblasts in vivo and in culture | Q34567113 |
| | Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis | Q35010724 |
| | Estrogen receptors in pancreatic tumors | Q36547155 |
| | Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma | Q36623544 |
| | Cancer of the pancreas. 50 years of surgery | Q39695304 |
| | Estrogen receptor beta/alpha ratio predicts response of pancreatic cancer cells to estrogens and phytoestrogens | Q40175356 |
| | Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in a murine xenograft model and CAM assay | Q40182528 |
| | Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients | Q40309801 |
| | TIMP-1 antisense gene transfection attenuates the invasive potential of pancreatic cancer cells in vitro and inhibits tumor growth in vivo | Q40418639 |
| | Matrilysin-2 (matrix metalloproteinase-26) is upregulated in keratinocytes during wound repair and early skin carcinogenesis | Q40437576 |
| | Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity | Q40519057 |
| | Invasiveness and MMP expression in pancreatic carcinoma | Q40804269 |
| | Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor | Q42500633 |
| | Pancreatitis and pancreatic cancer: a population-based study | Q42603974 |
| | Establishment of a continuous tumor-cell line (PANC-1) from a human carcinoma of the exocrine pancreas | Q42803605 |
| | Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. | Q43912549 |
| | Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness | Q44567936 |
| | Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. | Q44582763 |
| | Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. | Q44850177 |
| | Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo | Q45882304 |
| | Pancreatitis is a risk factor for pancreatic cancer | Q48638030 |
| | Cigarette smoking and pancreas cancer: a case control study of the search programme of the IARC. | Q51025229 |
| | Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. | Q52827022 |
| | Characterization of a new primary human pancreatic tumor line. | Q52828283 |
| | Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. | Q55036012 |
| | Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. | Q55064253 |
| | Expression and Prognostic Significance of Metalloproteinases and Their Tissue Inhibitors in Patients With Small-Cell Lung Cancer | Q57272687 |
| | Endometrial expression of the estrogen-sensitive genes MMP-26 and TIMP-4 is altered by a substitution protocol without down-regulation in IVF patients | Q57607660 |
| | TGF-?-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system | Q60609528 |
| | Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors | Q64377824 |
| | Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer | Q73507201 |
| | Expression of laminin-5-gamma-2 chain in intraductal papillary-mucinous and invasive ductal tumors of the pancreas | Q73881726 |
| | mRNA expression of matrix metalloproteases and their inhibitors differs in subtypes of renal cell carcinomas | Q74567830 |
| | Resection of pancreatic cancer normalizes the preoperative increase of tumor necrosis factor alpha gene expression | Q78367310 |
| | Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinase-3 and -4 in normal ovary and ovarian carcinoma | Q79160401 |
| | Expression profiles associated with aggressive behavior in Merkel cell carcinoma | Q79370590 |
| P433 | issue | 11 | |
| P921 | main subject | adenocarcinoma | Q356033 |
| P304 | page(s) | 1128-1140 | |
| P577 | publication date | 2007-09-14 | |
| P1433 | published in | Modern Pathology | Q15724578 |
| P1476 | title | Increased expression of matrix metalloproteinases-21 and -26 and TIMP-4 in pancreatic adenocarcinoma | |
| P478 | volume | 20 | |